Abstract
Cyclin-dependent kinase5 (Cdk5), involved in the processes of neuronal maturation and migration, is expressed in most tissues including proliferation cells. This research is aimed to use Cdk5 as a target for anticancer drug design. Virtual screening of Cdk5 by using Raccoon | AutoDock VS against the National Cancer Institute Diversity Set II has been performed. The selected compounds show binding energy between -10.43 to -8.53 kcal/mol and ligand efficiency values more than 0.40, which revealed 20 potential inhibitor candidates. Moreover, the binding energy of 10 compounds is related to their biological evaluation.These 10 inhibitors from NCI Diversity Set II serve as new Cdk5 inhibitors.
Keywords: Active site, cancer, cyclin-dependent kinases 5, drug design, raccon | autodock VS, virtual Screening.
Letters in Drug Design & Discovery
Title:Virtual Screening of NCI Diversity Set II Lead to New Cyclin-Dependent Kinases 5 Inhibitors Using AutoDock
Volume: 13 Issue: 3
Author(s): Siripit Pitchuanchom, Chavi Yenjai, Chantana Boonyarat, Stefano Forli and Arthur J. Olson
Affiliation:
Keywords: Active site, cancer, cyclin-dependent kinases 5, drug design, raccon | autodock VS, virtual Screening.
Abstract: Cyclin-dependent kinase5 (Cdk5), involved in the processes of neuronal maturation and migration, is expressed in most tissues including proliferation cells. This research is aimed to use Cdk5 as a target for anticancer drug design. Virtual screening of Cdk5 by using Raccoon | AutoDock VS against the National Cancer Institute Diversity Set II has been performed. The selected compounds show binding energy between -10.43 to -8.53 kcal/mol and ligand efficiency values more than 0.40, which revealed 20 potential inhibitor candidates. Moreover, the binding energy of 10 compounds is related to their biological evaluation.These 10 inhibitors from NCI Diversity Set II serve as new Cdk5 inhibitors.
Export Options
About this article
Cite this article as:
Pitchuanchom Siripit, Yenjai Chavi, Boonyarat Chantana, Forli Stefano and J. Olson Arthur, Virtual Screening of NCI Diversity Set II Lead to New Cyclin-Dependent Kinases 5 Inhibitors Using AutoDock, Letters in Drug Design & Discovery 2016; 13 (3) . https://dx.doi.org/10.2174/1570180812999150820161259
DOI https://dx.doi.org/10.2174/1570180812999150820161259 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
ARRDC3 Inhibits the Progression of Human Prostate Cancer Through ARRDC3-ITGβ4 Pathway
Current Molecular Medicine Congenital Malformations Attributed to Prenatal Exposure to Cyclophosphamide
Anti-Cancer Agents in Medicinal Chemistry Patent Selections
Recent Patents on Nanomedicine Chronic Myeloid Leukemia: Existing Therapeutic Options and Strategies to Overcome Drug Resistance
Mini-Reviews in Medicinal Chemistry From Multiple PAR1 Receptor/Protein Interactions to their Multiple Therapeutic Implications
Current Topics in Medicinal Chemistry Targeting CREB for Cancer Therapy: Friend or Foe
Current Cancer Drug Targets Antidiabetic Effect of Polyphenolic Extracts from Selected Edible Plants as α-Amylase, α -Glucosidase and PTP1B Inhibitors, and β Pancreatic Cells Cytoprotective Agents - A Comparative Study
Current Topics in Medicinal Chemistry Cyclooxygenase-2 Inhibitors: A Painful Lesson
Cardiovascular & Hematological Disorders-Drug Targets microRNA, Cancer and Cancer Chemoprevention
Current Molecular Pharmacology The Role of Pemetrexed in Advanced Non Small-Cell Lung Cancer: Special Focus on Pharmacology and Mechanism of Action
Current Drug Targets Editorial [Hot Topic: Steroid Nuclear Receptor Family (Guest Editor: Pedro H.H. Hermkens)]
Current Medicinal Chemistry Therapeutic Approaches Using Riboflavin in Mitochondrial Energy Metabolism Disorders
Current Drug Targets The Role of Survivin for Radiation Oncology: Moving Beyond Apoptosis Inhibition
Current Medicinal Chemistry Notch-Associated MicroRNAs in Cancer
Current Drug Targets Morphologic and Molecular Backgrounds for Personalized Management of Genito-Urinary Cancers: An Overview
Current Drug Targets 5-HT3 Receptors
Current Drug Targets - CNS & Neurological Disorders The Interaction of Histone Deacetylase Inhibitors and DNA Methyltransferase Inhibitors in the Treatment of Human Cancer Cells
Current Medicinal Chemistry - Anti-Cancer Agents Gene Expression Assay in the Management of Early Breast Cancer
Current Medicinal Chemistry Electric cable: cytoskeleton as an electric transmitter for cancer therapy
Current Signal Transduction Therapy Novel Strategies in Cancer Therapeutics: Targeting Enzymes Involved in Cell Cycle Regulation and Cellular Proliferation
Current Cancer Drug Targets